Kratom Interactions and Mixing: A Practical Safety Guide for Alcohol, Medications and Other Substances

The short answer

Kratom can have effects in the body, and the possibility of an
interaction cannot be judged from the word “natural,” a color name or a
familiar-looking package. The safest practical rule is to avoid
combining kratom with alcohol, opioids, benzodiazepines, sleep
medicines, stimulants or other psychoactive substances unless a
qualified health professional who knows the exact products has evaluated
the combination.

That recommendation is based on uncertainty as much as on known risk.
Human interaction studies are limited. Products vary. Labels do not
always provide enough information to compare exposure. A person may also
be taking prescription drugs, over-the-counter medicines, nicotine,
cannabis, alcohol, energy products or supplements at the same time.

The strongest current national surveillance signal concerns
multiple-substance exposures. A March 26, 2026 CDC analysis of National
Poison Data System reports from 2015 through 2025 found that
multiple-substance reports were associated with more hospitalizations
and serious outcomes than single-substance reports. Of 233
kratom-associated deaths reported in that dataset, 184—79%—involved
multiple substances. The study could not determine which substance
caused each outcome, and it could not reliably separate ordinary leaf
from concentrated or semisynthetic products. Those limitations matter.
The data support caution; they do not prove that every combination
produces the same result or that kratom alone caused every reported
outcome.

This guide explains what an “interaction” can mean, what a small
human study found, why product type changes the question and how to
prepare a useful conversation with a pharmacist or clinician.

What does “interaction” mean?

An interaction is not limited to two ingredients producing an
obviously dramatic reaction. It can happen in several ways.

1. Effects can add together

Two substances may push the same function in the same direction. For
example, more than one substance may contribute to sleepiness, impaired
coordination, nausea, changes in alertness or difficulty performing a
safety-sensitive task. Researchers call this a pharmacodynamic
interaction: the substances affect the body in overlapping
ways.

This does not require the products to use identical biological
pathways. Different mechanisms can still lead to a similar outward
effect. A label that says “botanical,” “herbal” or “plant based” does
not rule this out.

2. One
substance can change how another is processed

A substance may alter the absorption, metabolism or elimination of
another substance. This is a pharmacokinetic
interaction. The result could be more exposure, less exposure
or a change in how long an effect lasts.

Many medicines are processed by enzyme systems that include
cytochrome P450 enzymes. Laboratory evidence can identify a potential
mechanism, but laboratory results do not automatically reveal the size
of an interaction in a person. Human studies are needed because
preparation, amount, timing, genetics, diet, health conditions and other
medicines can change the outcome.

3. One
product can contain more than the buyer realizes

A combination may be unintentional. A “daytime” product could contain
caffeine or another stimulant. A liquid could contain alcohol as a
solvent. A multi-ingredient gummy may include cannabinoids, melatonin or
botanicals in addition to a kratom ingredient. A product advertised as
“kratom” might actually be a concentrated 7-hydroxymitragynine product
rather than ordinary leaf.

That is why interaction review starts with an ingredient list,
serving information, lot number and matching certificate of analysis—not
with the brand name alone.

4.
Impairment can matter before an emergency occurs

An interaction does not need to cause hospitalization to matter.
Drowsiness, dizziness, delayed reaction, poor coordination, agitation or
reduced judgment can create serious risks while driving, working at
height, using tools, caring for children or operating machinery. NHTSA
advises that interactions between alcohol and other substances can
increase impairment and make driving more dangerous. A person should not
use “I feel fine” as a driving test.

What the
best current human interaction study found

In 2023, researchers published a small controlled clinical study
involving 12 healthy adults. Participants received a low dose of kratom
tea prepared from 2 grams of leaf together with two probe medicines:
midazolam, used to evaluate CYP3A activity, and dextromethorphan, used
to evaluate CYP2D6 activity.

The kratom preparation did not meaningfully change the measured
overall exposure or peak concentration of dextromethorphan in that
study. It produced a modest increase in midazolam exposure: the
geometric mean ratios were 1.39 for area under the concentration-time
curve and 1.50 for peak concentration. The lack of a change in midazolam
half-life supported the researchers’ conclusion that the observed effect
primarily involved intestinal CYP3A.

That is useful evidence, but it has boundaries:

• It involved only 12 healthy adults.
• It evaluated a single, low-dose tea preparation, not every powder,
  capsule, extract, shot, gummy or enhanced product.
• It tested specific probe medicines under controlled conditions.
• It does not provide a list of all medicines that are safe or unsafe
  with kratom.
• It does not establish a waiting period that makes every combination
  safe.
• It does not establish the effects of frequent use, higher exposure
  or concentrated 7-OH products.

The correct takeaway is not “CYP3A medicines are always dangerous” or
“CYP2D6 medicines are cleared.” The study shows that a measurable human
interaction is possible and that broad conclusions from a single
experiment would be inappropriate.

Earlier laboratory and modeling work identified time-dependent
inhibition of CYP3A by mitragynine and helped justify the clinical
study. Laboratory predictions were larger than the interaction later
observed in the small human study. This difference is a good example of
why a test-tube finding should be treated as a warning signal, not a
personalized forecast.

What
national poison-center data can—and cannot—tell us

CDC’s 2026 report analyzed 14,449 kratom exposure reports involving
people age 12 and older from 2015 through 2025. Reports reached a record
3,434 in 2025, compared with 258 in 2015. The database contains calls
made to U.S. poison centers, so it does not measure every use, every
adverse event or the rate of harm among all consumers.

Multiple-substance reports made up 38% of the total dataset but were
associated with higher annual percentages of hospitalization and serious
outcomes than single-substance reports. Among the other substances
reported in multiple-substance cases were ethanol, opioids,
benzodiazepines, cannabis or cannabinoids, stimulants and
antidepressants.

The report’s most useful consumer lesson is simple:
multiple-substance situations deserve additional caution. Its
limitations prevent stronger claims:

• Poison-center reporting is voluntary and may miss events.
• A report documents an actual or suspected exposure that prompted
  consultation; it does not by itself prove causation.
• Product identity may be incomplete or inaccurate.
• The data did not distinguish ordinary botanical leaf from
  high-potency, concentrated or semisynthetic products.
• When several substances are present, the contribution of each one
  may be impossible to determine.

Good safety education should preserve both parts of the evidence:
multisubstance reports had worse observed outcomes, and the data cannot
predict what will happen to a particular person.

Why product
type changes the interaction question

“Kratom” is used as an umbrella word for products that can be very
different. Interaction advice is incomplete unless the product category
is identified.

Product category	What it generally means	Interaction-review issue
Whole or cut leaf	Dried botanical material	Alkaloid content still varies; identity, amount and other ingredients matter.
Plain powder	Ground botanical leaf	A scoop is not a standardized unit; mass and lot-specific testing matter.
Pure-leaf capsule	Botanical powder inside a capsule	Capsule format does not make the contents an extract. Kiody’s leaf capsules are approximately 500 mg each.
Extract	Material concentrated from leaf	An extraction ratio alone does not reveal alkaloid exposure. Review milligrams, percentages and serving information.
Enhanced leaf	Leaf combined with an extract or added alkaloid material	The same mass may not be comparable with plain leaf. Uniformity and disclosure are especially important.
Concentrated 7-OH	Product formulated to deliver elevated or isolated 7-hydroxymitragynine	Do not treat it as ordinary botanical leaf. Kiody does not sell concentrated 7-OH.
Manufactured derivative	A synthesized, semisynthesized or intentionally manufactured compound	Federal and state controlled-substance rules may apply independently of botanical-leaf law.
Multi-ingredient product	Kratom ingredient plus flavors, stimulants, cannabinoids, botanicals or other actives	Every active ingredient and the complete serving must be reviewed.

FDA’s current materials distinguish natural leaf containing minor,
naturally occurring 7-OH from products enriched with isolated 7-OH. CDC
likewise notes that high-potency products marketed as kratom can be
distinct from traditional leaf preparations. That distinction is
important for chemistry, labeling, legal review and responsible-use
education.

Kratom and alcohol

There is not enough controlled human research to calculate a
universally safe kratom-and-alcohol combination. National poison-center
surveillance identifies ethanol as a commonly reported co-exposure, and
19% of the kratom-associated fatalities in the 2015–2025 dataset
included ethanol. That percentage does not establish that alcohol caused
those deaths, but it is a meaningful signal against casual mixing.

Alcohol also impairs judgment, coordination and reaction. NIAAA warns
that alcohol can intensify drowsiness, dizziness and loss of
coordination caused by medicines, and that harmful interactions may
occur even when the products are not taken at exactly the same time.
Because kratom product composition and individual responses vary, a
clock-based rule such as “wait two hours” is not supported by the
evidence.

Practical safety position:

• Do not use alcohol to “balance,” intensify or reverse a kratom
  effect.
• Do not combine them before driving, operating equipment or
  performing safety-sensitive work.
• Do not assume a lower-alcohol beverage makes the combination
  predictable.
• Remember that tinctures, flavor extracts, cough products or other
  liquids may themselves contain alcohol.
• If an unexpected reaction occurs, stop taking more substances and
  contact Poison Help or emergency services as appropriate.

This is risk-reduction language, not a claim that every co-use
produces an emergency.

Kratom
with opioids, benzodiazepines and other sedating products

CDC’s 2026 analysis found opioids in 62% of reported
kratom-associated fatalities and benzodiazepines in 20%. Again,
toxicology association does not prove which substance caused an
individual death. It does show that these combinations appear often
enough in serious reports to warrant a strong caution.

Sedating medicines and products can include prescription opioids,
benzodiazepines, sleep medicines, certain antihistamines, some muscle
relaxants and other agents. A product does not need to be a prescription
drug to contribute to drowsiness or impaired coordination. Alcohol and
cannabis may add further uncertainty.

Someone taking a prescribed medicine should not stop it abruptly
because they read about a possible interaction. The appropriate next
step is to show the complete product label and medication list to a
pharmacist or prescriber. Useful questions include:

1. Is this medicine associated with sedation, slowed breathing,
   dizziness or impaired coordination?
2. Is it substantially metabolized by CYP3A or another pathway that
   makes an interaction plausible?
3. Does the medicine have a narrow therapeutic range or require
   blood-level monitoring?
4. Does the product contain multiple active ingredients?
5. Are there safer ways to avoid overlapping effects?

The answer depends on the exact medicine, product and person. A
generic internet list cannot replace that review.

Kratom with
stimulants and “energy” products

Stimulants accounted for 11% of the other substances in
multiple-substance poison-center reports and appeared in 20% of reported
kratom-associated fatalities in CDC’s dataset. The stimulant category
included prescription and nonprescription substances such as
amphetamines, cocaine, methamphetamine, methylphenidate and related
compounds.

Consumer products may also contain caffeine or other stimulating
ingredients. Combining substances because one is marketed as “energy”
and another as “relaxation” does not guarantee that the effects cancel
out. A person may instead experience an unpredictable mix of changes in
alertness, heart rate, blood pressure, anxiety, coordination or
judgment.

Avoid “stacking” products to chase a desired feeling. If a label does
not fully disclose active ingredients and their amounts, that
uncertainty is itself a reason not to combine it with another
psychoactive product.

Kratom
with antidepressants and other psychiatric medicines

Antidepressants were reported in 14% of CDC’s multiple-substance
kratom exposures. The database does not establish a specific interaction
for every antidepressant. This medication category contains drugs with
different mechanisms, metabolism and risk profiles, so one blanket rule
would be misleading.

Do not use a list of brand names as a substitute for professional
review. A pharmacist needs the generic drug name, strength, schedule,
other medicines and the exact kratom product. The most useful action is
disclosure: bring the bottle, a clear label photo or a printed
ingredient panel.

Anyone experiencing a mental-health crisis or thoughts of self-harm
should seek immediate help. In the United States, call or text
988 for the Suicide & Crisis Lifeline. If there is
immediate danger, call 911.

Kratom with cannabis or
cannabinoids

Cannabis and cannabinoid products accounted for 12% of the other
substances reported in CDC’s multiple-substance exposure cases. That
finding does not quantify the risk of every possible combination or
distinguish THC, CBD, concentrates, edibles and synthetic
cannabinoids.

The practical concern is overlapping and unpredictable effects. A
cannabis edible may have a delayed onset, a kratom product may be
mislabeled or concentrated, and both products may be taken again before
their full effects are understood. Avoid driving or safety-sensitive
activity and avoid adding more products to correct an unwanted
effect.

Over-the-counter
medicines still count

“Nonprescription” does not mean “interaction free.” Cold, cough,
allergy, motion-sickness and sleep products may contain ingredients that
affect alertness or are metabolized through relevant pathways.
Combination products may contain two, three or more active ingredients
under one brand name.

Read the active ingredients panel, not only the
front label. A pharmacist can review over-the-counter products as well
as prescriptions. Bring the package or a photo that clearly shows active
ingredients, strength and directions.

Do not overlook products such as:

• Nighttime cold or sleep formulations
• Sedating antihistamines
• Dextromethorphan-containing cough products
• Decongestants and stimulant-like ingredients
• Pain relievers combined with additional actives
• Liquid medicines containing alcohol

This list identifies categories to review; it is not a statement that
every product in a category has a proven kratom interaction.

A
label-and-COA review before discussing interactions

A clinician cannot evaluate a product that is described only as
“green,” “red,” “white,” “strong” or “premium.” Gather the following
information first:

1. Exact product name and manufacturer. Record what
   appears on the package.
2. Lot or batch number. The COA should match this
   identifier.
3. Product category. Leaf, pure-leaf capsule, extract,
   enhanced product, concentrated 7-OH or multi-ingredient blend.
4. Full ingredient list. Include “other ingredients,”
   flavors, sweeteners and capsule materials.
5. Serving size and servings per container. Do not
   substitute a scoop estimate for a stated mass.
6. Alkaloid declaration. Note percentages, mg/g, mg/mL
   and milligrams per serving exactly as printed.
7. 7-OH information. Record the result, reporting
   unit, basis and reporting limit.
8. COA identity. Laboratory, report number, sample
   name, date and method.
9. Your complete medication list. Prescriptions, OTC
   drugs, supplements and intermittent products.
10. Alcohol, nicotine, cannabis and energy-product use.
    These are relevant even if they are not “medicines.”

A COA helps identify composition and contaminants. It cannot certify
that a combination is safe for a particular person.

Twelve
questions to take to a pharmacist or clinician

Use these questions as a conversation guide, not a self-diagnosis
tool:

1. Does any medicine on this list cause drowsiness, dizziness or
   impaired coordination?
2. Does any medicine affect breathing, blood pressure, heart rhythm or
   seizure risk?
3. Is any medicine primarily processed by CYP3A or another pathway of
   concern?
4. Does any medicine have a narrow therapeutic range?
5. Could kidney or liver function change the assessment?
6. Are there duplicate active ingredients in my prescription and OTC
   products?
7. Does the product label disclose enough to review it?
8. Does an extract or enhanced product create more uncertainty than
   plain leaf?
9. Are there alcohol-containing liquid medicines on the list?
10. Should any planned surgery, anesthesia or laboratory monitoring
    change the advice?
11. What symptoms should prompt Poison Help, urgent care or 911?
12. How should I document and report an unexpected reaction?

Do not ask a clinician to approve a color or marketing term. Ask them
to review ingredients, exposure information and the whole medication
list.

A responsible-use decision
process

Step 1: Identify the exact
product

Do not proceed from a generic claim such as “it is just kratom.”
Determine whether it is botanical leaf, extract, enhanced leaf,
concentrated 7-OH or a manufactured derivative.

Step 2: Reject incomplete
labels

If active ingredients, serving size, manufacturer and lot number are
missing, the product cannot be meaningfully evaluated. Do not use a QR
code as an excuse for missing core package information.

Step 3: Match the COA

The lot on the report should match the lot on the package. Review
alkaloid results and units. A report for a different lot is not evidence
for the product in hand.

Step 4: Build one complete
list

Include prescriptions, OTC medicines, supplements, alcohol, cannabis,
nicotine and energy products. Include products used only
occasionally.

Step 5: Flag
high-uncertainty situations

Examples include multiple psychoactive products, concentrated
extracts, missing labels, recent medication changes, planned surgery,
pregnancy or breastfeeding, history of seizures, significant liver or
kidney disease, or a previous unexpected reaction. These situations need
professional review and may support avoiding the product entirely.

Step 6: Ask before
changing treatment

Contact a pharmacist or prescriber. Do not stop a prescription
suddenly and do not replace prescribed care with kratom.

Step 7: Avoid mixing
to manipulate effects

Do not add alcohol, sedatives, stimulants or other substances to
intensify, extend, cancel or reverse an effect.

Step 8: Protect driving
and work safety

Do not drive, climb, supervise hazardous equipment or perform
safety-sensitive work if alertness, coordination or judgment could be
affected.

Step 9: Keep the package

If an adverse event occurs, responders need the container, lot
number, ingredient list and COA. Do not discard them.

Step 10: Know the response
numbers

Call 911 for collapse, seizure, trouble breathing or inability to
awaken. Contact Poison Help at 1-800-222-1222 for immediate exposure
guidance. Contact 988 for a mental-health or suicide crisis.

Step 11: Report
suspected adverse events

FDA encourages consumers and health professionals to report suspected
kratom reactions through MedWatch. A report can be useful even when
causation is uncertain.

Step 12: Reassess when
anything changes

A different lot, new prescription, changed health condition, new
product format or new state rule can change the review. Past experience
does not guarantee the next situation will be the same.

Five fictional examples

These examples illustrate reasoning. They are not medical
recommendations.

Example
1: Plain-leaf capsules plus a new prescription

The bottle identifies pure-leaf capsules, approximately 500 mg each,
and the lot matches the COA. The consumer has just started a
prescription and asks whether their previous routine is still
appropriate.

Better decision: Pause and ask a pharmacist to
review the generic medicine, strength, schedule, product label and COA.
A clean COA does not answer the interaction question.

Example
2: An “energy shot” with an incomplete ingredient list

The front says “kratom energy,” but the label does not disclose
whether the product is leaf, extract or enhanced material. Caffeine is
mentioned in marketing copy but not quantified.

Better decision: Do not combine it with another
stimulant or psychoactive product. The incomplete label prevents a
meaningful review.

Example
3: Alcohol added to offset an unwanted feeling

Someone feels uncomfortable after using a kratom product and
considers drinking alcohol to calm down.

Better decision: Do not add alcohol or another
substance. Stop taking more products, avoid driving and contact Poison
Help for case-specific guidance if there is concern.

Example
4: A product advertised as leaf with 7-OH milligrams per tablet

The product is marketed as “natural kratom,” but each tablet declares
a specific milligram quantity of 7-OH.

Better decision: Do not treat it as ordinary leaf.
It is a concentrated 7-OH presentation requiring separate health and
legal review. Kiody does not sell concentrated 7-OH.

Example 5: A
familiar product, different lot

The consumer has used the brand before, but the new package has a
different lot number and an updated ingredient panel.

Better decision: Treat it as a new review. Match the
new lot to its COA and check the entire ingredient list and medication
list again.

Warning
signs in interaction content and product marketing

Use caution when a seller or article:

• Says “natural means no interactions”
• Claims a product is safe with every medication
• Uses a strain color as a medical prediction
• Gives an exact universal waiting period without evidence
• Tells readers to stop a prescription
• Says a COA proves personal safety
• Treats all extracts as equivalent to leaf
• Treats concentrated 7-OH as ordinary powder
• Ignores alcohol, cannabis or OTC medicines
• Lists only brand names and not active ingredients
• Describes laboratory enzyme findings as guaranteed human
  outcomes
• Uses one small study to declare an entire drug class safe
• Omits the study dose and product preparation
• Confuses association with causation in toxicology data
• Hides serving size or alkaloid units
• Uses “pharmacist approved” without verifiable scope or
  documentation
• Says lack of a known report proves lack of risk
• Encourages “stacking” to correct effects
• Promotes use before driving or safety-sensitive work
• Makes disease-treatment or withdrawal-treatment promises

Current
federal product distinction as of September 3, 2026

Federal developments make precise product language especially
important.

The federal proceeding for 7-hydroxymitragynine above a
specified threshold remains proposed. HHS extended the
public-comment period through September 10, 2026. The
notice describes a threshold-focused process intended to distinguish
above-threshold 7-OH products from natural botanical leaf containing
trace amounts. A proposal is not a final scheduling order.

Separately, DEA’s temporary Schedule I order for mitragynine
pseudoindoxyl, MGM-15 and MGM-16 became effective
August 26, 2026 and is scheduled to remain in effect
through August 26, 2028 unless extended or replaced under the Controlled
Substances Act process. DOJ later stated an incidental-trace enforcement
policy for mitragynine pseudoindoxyl in products otherwise consistent
with botanical kratom; that policy is not a legal exemption and does not
cover intentionally manufactured, concentrated or fortified material,
MGM-15 or MGM-16.

This guide does not use federal status to infer state legality. State
and local rules can be more restrictive, and product thresholds use
different units and denominators. Check Kiody’s nationwide leaf and 7-OH
trackers for dated primary sources. Kiody is 21+ and does not sell
concentrated 7-OH.

Frequently asked questions

Does kratom interact
with every medication?

No. Evidence does not support that blanket statement. Evidence also
does not support assuming that no interaction exists. The correct
assessment depends on the medicine, pathway, product, amount, pattern of
use and individual factors.

Can a pharmacist
check kratom interactions?

A pharmacist can review the medication list, known pathways,
overlapping effects and uncertainty. Bring the exact product label,
lot-specific COA and complete list of prescriptions, OTC medicines and
supplements.

Is
kratom safe with alcohol if they are used hours apart?

No universal waiting period has been established. NIAAA notes that
alcohol can interact with medicines even when they are not taken at the
same time. Product variability and limited kratom-specific research make
a simple clock rule unreliable.

Does a clean
COA mean there are no interactions?

No. A COA may report identity, alkaloids or contaminants. It does not
evaluate a consumer’s medication list or certify a combination as
safe.

Are pure-leaf capsules an
extract?

Not necessarily. A capsule can simply contain ground botanical leaf.
Kiody’s pure-leaf capsules contain approximately 500 mg of leaf per
capsule. Check the ingredient panel instead of judging the format.

Is concentrated
7-OH the same as botanical leaf?

No. Natural leaf can contain minor amounts of 7-OH, while
concentrated products are formulated to deliver elevated or isolated
7-OH. Health and legal questions should distinguish them. Kiody does not
sell concentrated 7-OH.

What did the human CYP study
prove?

It showed a modest increase in midazolam exposure after a particular
2-gram kratom tea preparation in 12 healthy adults, with no meaningful
change in the dextromethorphan measures studied. It did not test every
medicine, product type, amount or use pattern.

Does
no CYP2D6 effect in that study mean all CYP2D6 medicines are safe?

No. That conclusion would go beyond the study. One probe, one
preparation and one small participant group cannot clear an entire class
of medicines or every pattern of use.

Why avoid mixing if
causation is uncertain?

Risk decisions often account for incomplete information. CDC observed
more severe outcomes in multiple-substance poison-center reports and
frequent co-reporting of alcohol, opioids, benzodiazepines, stimulants
and antidepressants. Avoiding unnecessary combinations reduces
uncertainty.

Can one substance cancel
another out?

Do not count on it. A stimulant and sedating substance may create an
unpredictable combination rather than neutralizing each other. Adding a
second product can complicate symptoms and delay appropriate help.

Do over-the-counter
medicines matter?

Yes. OTC products may contain sedating, stimulating or interacting
ingredients, and combination products can contain several actives.
Review the active-ingredient panel with a pharmacist.

Should
someone stop a prescription before using kratom?

Not without the prescriber’s direction. Abruptly stopping some
medicines can be dangerous. Discuss the product and medication list with
a qualified clinician.

Is “all
natural” evidence that a combination is safe?

No. FDA and NIH both emphasize that plant-derived ingredients can
have strong biological effects and may interact with medicines.

When should someone call 911?

Call 911 for collapse, seizure, trouble breathing or inability to
awaken. Do not wait for an online answer.

What is Poison Help’s number?

In the United States, call 1-800-222-1222.
Poison-center specialists provide immediate, case-specific exposure
guidance.

Should the
original package be kept after a reaction?

Yes. Keep the container, label, lot number, receipt and COA. Those
details can help poison-center staff, clinicians, the manufacturer and
FDA understand the event.

Can a
consumer report a suspected reaction even without proof?

Yes. FDA’s MedWatch system accepts suspected adverse-event and
product-problem reports. Reporting does not require the consumer to
prove causation.

Does Kiody sell concentrated
7-OH?

No. Kiody focuses on adults 21+ and does not sell concentrated 7-OH
products.

Sources

1. U.S. Food and Drug Administration, FDA and Kratom:
   https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
2. Centers for Disease Control and Prevention, Towers EB et al.,
   Increases in Kratom-Related Reports to Poison Centers—National
   Poison Data System, United States, 2015–2025, MMWR, March 26,
   2026: https://www.cdc.gov/mmwr/volumes/75/wr/mm7511a1.htm
3. Tanna RS et al., Clinical Assessment of the Drug Interaction
   Potential of the Psychotropic Natural Product Kratom,
   Clinical Pharmacology & Therapeutics (2023), PubMed PMID
   36924284: https://pubmed.ncbi.nlm.nih.gov/36924284/
4. Tanna RS et al., full-text article in PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC10198846/
5. U.S. Food and Drug Administration, FDA’s Regulation of
   Dietary Supplements with Dr. Cara Welch: https://www.fda.gov/drugs/news-events-human-drugs/fdas-regulation-dietary-supplements-dr-cara-welch
6. NIH Office of Dietary Supplements, Dietary Supplements: What
   You Need to Know: https://ods.od.nih.gov/factsheets/WYNTK-Consumer/
7. National Institute on Alcohol Abuse and Alcoholism, Harmful
   Interactions: Mixing Alcohol With Medicines: https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/harmful-interactions-mixing-alcohol-with-medicines
8. National Highway Traffic Safety Administration, Drunk
   Driving—Interactions and Impairment: https://www.nhtsa.gov/risky-driving/drunk-driving
9. Poison Help: https://www.poisonhelp.org/ and
   1-800-222-1222
10. FDA MedWatch: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
11. FDA, Hiding in Plain Sight: 7-OH Products: https://www.fda.gov/news-events/public-health-focus/hiding-plain-sight-7-oh-products
12. Federal Register, 7-Hydroxymitragynine Above a Specified
    Threshold in Schedule I; Extension of Comment Period, August
    26, 2026: https://www.federalregister.gov/documents/2026/08/26/2026-17409/hydroxymitragynine-above-a-specified-threshold-in-schedule-i-extension-of-comment-period
13. Federal Register, Temporary Placement of Mitragynine
    Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I, effective
    August 26, 2026: https://www.federalregister.gov/documents/2026/08/26/2026-17429/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindoxyl-mgm-15-and
14. U.S. Department of Justice, September 1, 2026 MGPI enforcement
    clarification: https://www.justice.gov/opa/pr/justice-department-announces-emergency-scheduling-three-potent-opioid-compounds
15. 988 Suicide & Crisis Lifeline: https://988lifeline.org/